Onkologie. 2020:14(4):169-171 | DOI: 10.36290/xon.2020.060

Male greast cancer - late dissemination into the skeleton

Jitka Abrahámová1, Daniel Klika2, Lucia Kaliská2, Darja Šustrová3
1 Proton Therapy Center Czech, s. r. o., Praha; KOC (NNB + VFN + TN)
2 Proton Therapy Center Czech, s. r. o., Praha
3 Onkologická klinika 2. LF UK a FN Motol, Praha

The case report describes a case of a patient with male breast cancer diagnosed in the age of 49 years. The man underwent a surgery chemotherapy, radiotherapy and hormonal therapy, acording the treatment standard in that time (Y 1996). 23 years later he developed pathological process in his skeleton. Authors describe very difficult way to the diagnosis of the skeletal metastatic breast cancer. They emphasize the posibility of very late dissemination of male breast cancer even in the absence of any risk faktors.

Keywords: male breast cancer, metastatic disease, PET, CT.

Published: September 23, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Abrahámová J, Klika D, Kaliská L, Šustrová D. Male greast cancer - late dissemination into the skeleton. Onkologie. 2020;14(4):169-171. doi: 10.36290/xon.2020.060.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abdelwahab Y. AJ. Male Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol 2017; (44): 267-272. doi: 10.1053/j.seminoncol.2017.11.002. Go to original source... Go to PubMed...
    2. Abrahámová J, Malúšková D, Mužík J. Karcinom prsu u mužů (porovnání literárních údajů s vlastním materiálem a údaji NOR). Breast Cancer News, 2017; 7(1): 20-27.
    3. Abrahámová J, Krejčí D, Mužík J. Karcinom prsu u mužů (aktualizace údajů). Onkologie, 2020.
    4. Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018; 29: 405-417. doi: 10.1093/annons/mdx651. Go to original source...
    5. Giordano S. Breast Cancer in Men. The New England Journal of Medicine (review article) N Engl J Med, 2018; 378: 2311-2320. DOI: 10.1056/NEJMra1707939. Go to original source... Go to PubMed...
    6. Gucalp A, Traina TA, Einster JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019; 173: 37-48. doi: 10.1007/s10549-018-4921-9. Go to original source... Go to PubMed...
    7. Leon-Ferre RA, Giridhar KV, Hieken TJ, et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev. 2018; 37: 599-614. doi: 10.1007/s10555-018-9761-x. Go to original source... Go to PubMed...
    8. Zamagni C, Campone M, Kudryavcev I, et al. Ribociclib/RIBO + letrozol (LET) in male patients (PTS) with hormoen receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for advanced breast cancer: Preliminary subgroup results from the phase 3B CompLEEment. ESMO Congress 2018 Poster Discussion session, 21 Oct 2018. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.